<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549467</url>
  </required_header>
  <id_info>
    <org_study_id>IDEAA 002</org_study_id>
    <nct_id>NCT04549467</nct_id>
  </id_info>
  <brief_title>Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Patients</brief_title>
  <acronym>D2ARLING</acronym>
  <official_title>Efficacy of Dolutegravir Plus Lamivudine Compared to Dolutegravir Plus Tenofovir/Emtricitabine in HIV-1-infected Treatment-naïve Adults Without Baseline Genotyping Test (D2ARLING Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundacion IDEAA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundacion IDEAA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of DTG + 3TC versus DTG + TDF/FTC over&#xD;
      48 weeks in HIV-1 naive patients in a real life setting with no baseline HIV genotypic&#xD;
      resistance testing available.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 48-week, Phase IV, randomized, open-label, to assess the non-inferior antiviral&#xD;
      activity (VL &lt; 50 c/ml) of 2DR DTG+3TC versus 3DR TDF/FTC + DTG over 48 weeks in HIV1 naïve&#xD;
      adult patients without baseline GT available at Day 1 visit. Subjects will be stratified by&#xD;
      screening HIV-1 RNA (≤100,000 c/mL or &gt;100,000 c/mL) and Screening CD4+ cell count (≤ or &gt;200&#xD;
      cells/mm3).&#xD;
&#xD;
      The study will comprise:&#xD;
&#xD;
        -  a 28-day Screening Phase (which may be extended to 35 days to allow receipt of all&#xD;
           Screening assessment results).&#xD;
&#xD;
        -  an Open-label Randomized Phase (Day 1 to Week 48).&#xD;
&#xD;
      Approximately 200 HIV-1 naïve adult patients will be randomized 1:1 to receive 2DR DTG+3TC&#xD;
      versus 3DR TDF/FTC + DTG for 48 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virologic Efficacy</measure>
    <time_frame>48 weeks</time_frame>
    <description>To demonstrate the non-inferior antiviral activity (VL &lt; 50 c/ml) of 2DR DTG+3TC versus 3DR TDF/FTC + DTG over 48 weeks in HIV-1 naïve adult patients without baseline genotypic resistance testing available. Endpoint: Proportion of subjects with plasma HIV-1 RNA &lt;50 copies/mL (c/mL) at Week 48 using the FDA Snapshot algorithm [Missing, Switch or Discontinuation = Failure (MSD=F)] for the intent-to-treat exposed (ITT-E) population.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Genetic barrier</measure>
    <time_frame>48 weeks</time_frame>
    <description>To assess the selection / emergence of viral resistance in subjects meeting confirmed virologic withdrawal (CVW) criteria. Endpoint: incidence of treatment-emergent genotypic resistance to DTG and 3TC or TDF/FTC in subjects meeting CVW criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy in presence of any major resistanceassociated mutation al baseline</measure>
    <time_frame>48 weeks</time_frame>
    <description>To evaluate the antiviral activity of DTG + 3TC compared to DTG + TDF/FTC over time in patients with pre-existing viral resistance based on the presence of any major resistanceassociated mutation (IAS-USA 2019). Endpoint: Proportion of subjects with plasma HIV-1 RNA &lt;50 copies/mL (c/mL) at Week 48 using the FDA Snapshot algorithm and The proportion of participants with HIV-1 RNA &lt;50 or &lt;200 copies/mL using the observed algorithm (excluding participants with missing data) in patients with pre-existing viral resistance based on the presence of any major resistance-associated mutation (IAS-USA 2019).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hiv</condition>
  <condition>HIV-1-infection</condition>
  <arm_group>
    <arm_group_label>Dolutegravir + lamivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dolutegravir 50 mg, 1 tablet QD plus lamivudine 300 mg, 1 tablet QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dolutegravir + emtricitabine/tenofovir (FTC/TDF)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dolutegravir 50 mg, 1 tablet QD plus FTC/TDF 200/300 mg, 1 coformulated tablet QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamivudine 300 MG</intervention_name>
    <description>Experimental arm</description>
    <arm_group_label>Dolutegravir + lamivudine</arm_group_label>
    <other_name>3TC</other_name>
    <other_name>dolutegravir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Emtricitabine / Tenofovir Disoproxil Pill</intervention_name>
    <description>Active Comparator</description>
    <arm_group_label>Dolutegravir + emtricitabine/tenofovir (FTC/TDF)</arm_group_label>
    <other_name>truvada</other_name>
    <other_name>dolutegravir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject should be antiretroviral naïve (defined as &lt;=10 days of prior therapy with any&#xD;
             antiretroviral agent following a diagnosis of HIV 1 infection).&#xD;
&#xD;
          2. Age ≥ 18 years&#xD;
&#xD;
          3. Screening plasma HIV-1 RNA ≥1000 c/mL&#xD;
&#xD;
          4. CD4 cell count nadir: any value&#xD;
&#xD;
          5. Effective contraception for women of childbearing potential.&#xD;
&#xD;
          6. Informed consent form signed by patient and investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of suicide ideation, intention or action.&#xD;
&#xD;
          2. Evidence of HBV infection based on the results of testing at Screening* for HBV&#xD;
             surface antigen (HBsAg), HBV core antibody (anti-HBc), HBV surface antibody (antiHBs&#xD;
             or HBsAb), and HBV DNA as follows: Subjects positive for HBsAg are excluded; Subjects&#xD;
             negative for anti-HBs and HBsAg but positive for anti-HBc and positive for HBV DNA are&#xD;
             excluded.&#xD;
&#xD;
          3. Anticipated need for any HCV therapy during the first 48 weeks of the study.&#xD;
&#xD;
          4. Acute symptomatic HIV Infection.&#xD;
&#xD;
          5. Any active Opportunistic Infection (category C, CDC 2014).&#xD;
&#xD;
          6. Current pregnancy or breastfeeding.&#xD;
&#xD;
          7. No effective contraception for the women of childbearing.&#xD;
&#xD;
          8. Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during&#xD;
             the Screening period to verify a result.&#xD;
&#xD;
          9. ALT (Alanine Aminotransferase) ≥ 5 x upper limit of normal value (ULN) or AST&#xD;
             (Aspartate Aminotransferase) ≥ 3 x ULN and bilirubinemia ≥ 1.5 x ULN (with 35% direct&#xD;
             bilirubinemia).&#xD;
&#xD;
         10. Unstable liver disease (ascitis, encephalopathy, coagulopathy, hypoalbuminemia,&#xD;
             oesophageal or gastric varices or persistent jaundice).&#xD;
&#xD;
         11. Creatinine clearance of &lt;50 mL/min/1.73 m2 (Cockroft-Gault method).&#xD;
&#xD;
         12. History or presence of allergy to the trial drugs or their components.&#xD;
&#xD;
         13. Severe hepatic insufficiency (Child Pugh Class C).&#xD;
&#xD;
         14. Any available historical resistance test result.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ezequiel Cordova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion IDEAA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ezequiel Cordova</last_name>
    <phone>+54 11 4904-0623</phone>
    <email>dr_ecordova@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fundacion IDEAA</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1405</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <contact>
      <last_name>Ezequiel Cordova, MD</last_name>
      <phone>+54 11 4904-0623</phone>
      <email>dr_ecordova@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Ezequiel Cordova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <link>
    <url>http://fundacionideaa.com.ar/</url>
    <description>Fundacion IDEAA web page</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hiv</keyword>
  <keyword>antiretroviral treatment</keyword>
  <keyword>dolutegravir</keyword>
  <keyword>dual therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Emtricitabine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

